Azo compounds
Medchemexpress LLC CAY 10465 | 688348-33-6 | 98.3% | 317.13 | 1 ML
CAY 10465 is a selective and high-affinity AhR agonist with a Ki of 0.2 nM. It demonstrates no effect on the estrogen receptor (Ki >100000 nM). This compound reduces apolipoprotein A-I (apo A-I) levels in HepG2 cells and inhibits the synthesis of the protein.
- Selective and high-affinity AhR agonist
- No effect on estrogen receptor
- Reduces apolipoprotein A-I levels in HepG2 cells
- Inhibits protein synthesis
Selleck Chemical LLC APG-2449-E1508-1G
APG-2449 is an orally active inhibitor of ALK/ROS1/FAK APG-2449 exerts potent and durable antitumor activity in human non-small-cell lung cancer (NSCLC) and ovarian tumor models
Selleck Chemical LLC APG-2449-E1508-100MG
APG-2449 is an orally active inhibitor of ALK/ROS1/FAK APG-2449 exerts potent and durable antitumor activity in human non-small-cell lung cancer (NSCLC) and ovarian tumor models
Selleck Chemical LLC APG-2449-E1508-25MG
APG-2449 is an orally active inhibitor of ALK/ROS1/FAK APG-2449 exerts potent and durable antitumor activity in human non-small-cell lung cancer (NSCLC) and ovarian tumor models
Selleck Chemical LLC APG-2449-E1508-5MG
APG-2449 is an orally active inhibitor of ALK/ROS1/FAK APG-2449 exerts potent and durable antitumor activity in human non-small-cell lung cancer (NSCLC) and ovarian tumor models
Medchemexpress LLC KW-2449 | 1000669-72-6 | 99.9% | 332.40 | 10 MG
KW-2449 is a multi-targeted kinase inhibitor that targets FLT3, ABL, ABLT315I, and Aurora kinase with IC50 values of 6.6, 14, 4, and 48 nM, respectively. It is intended for research use only.
- Targets FLT3, ABL, ABLT315I, and Aurora kinase.
- Exhibits antiproliferative activity against imatinib-resistant K562 cells.
- Inhibits FLT3-mediated STAT5 phosphorylation.
- Increases G1 phase cells and promotes apoptosis.
- Suppresses tumor growth in FLT3-mutated xenograft models.
- Helps release imatinib resistance.
Apexbio Technology LLC KW 2449 1000669-72-6 50mg
KW 2449 (CAS 1000669-72-6) is a multi-targeted kinase inhibitor with potent activity against FLT3 (IC50 6 6 nM) ABL (14 nM) Aurora kinases (4 nM) and FGFR (48 nM) It inhibits both wild-type and T315I-mutated ABL tyrosine kinase In vitro KW 2449 disrupts proliferation through modulation of distinct signaling pathways it downregulates FLT3/STAT5 phosphorylation and induces G1-phase arrest and apoptosis in FLT3-mutated leukemia cells while promoting G2/M arrest via reduced histone H3 phosphorylation in FLT3 wild-type cells KW 2449 is applied in research investigating kinase-driven leukemias and resistance mechanisms to targeted therapies
Apexbio Technology LLC KW 2449 1000669-72-6 200mg
KW 2449 (CAS 1000669-72-6) is a multi-targeted kinase inhibitor with potent activity against FLT3 (IC50 6 6 nM) ABL (14 nM) Aurora kinases (4 nM) and FGFR (48 nM) It inhibits both wild-type and T315I-mutated ABL tyrosine kinase In vitro KW 2449 disrupts proliferation through modulation of distinct signaling pathways it downregulates FLT3/STAT5 phosphorylation and induces G1-phase arrest and apoptosis in FLT3-mutated leukemia cells while promoting G2/M arrest via reduced histone H3 phosphorylation in FLT3 wild-type cells KW 2449 is applied in research investigating kinase-driven leukemias and resistance mechanisms to targeted therapies
Medchemexpress LLC CAY 10465 | 688348-33-6 | 98.3% | 317.13 | 10 MG
CAY 10465 is a selective and high-affinity AhR agonist, with a Ki of 0.2 nM, and shows no effect on estrogen receptor (Ki >100000 nM). It is intended for research use only. This compound has been shown to reduce apolipoprotein A-I (apo A-I) levels in HepG2 cells and inhibit protein synthesis.
- Selective and high-affinity AhR agonist
- Ki of 0.2 nM
- No effect on estrogen receptor (Ki >100000 nM)
- Reduces apolipoprotein A-I (apo A-I) levels in HepG2 cells
- Inhibits protein synthesis
- Intended for research use only
Apexbio Technology LLC KW 2449 1000669-72-6 10mM (in 1mL DMSO)
KW 2449 (CAS 1000669-72-6) is a multi-targeted kinase inhibitor with potent activity against FLT3 (IC50 6 6 nM) ABL (14 nM) Aurora kinases (4 nM) and FGFR (48 nM) It inhibits both wild-type and T315I-mutated ABL tyrosine kinase In vitro KW 2449 disrupts proliferation through modulation of distinct signaling pathways it downregulates FLT3/STAT5 phosphorylation and induces G1-phase arrest and apoptosis in FLT3-mutated leukemia cells while promoting G2/M arrest via reduced histone H3 phosphorylation in FLT3 wild-type cells KW 2449 is applied in research investigating kinase-driven leukemias and resistance mechanisms to targeted therapies
Apexbio Technology LLC KW 2449 1000669-72-6 10mg
KW 2449 (CAS 1000669-72-6) is a multi-targeted kinase inhibitor with potent activity against FLT3 (IC50 6 6 nM) ABL (14 nM) Aurora kinases (4 nM) and FGFR (48 nM) It inhibits both wild-type and T315I-mutated ABL tyrosine kinase In vitro KW 2449 disrupts proliferation through modulation of distinct signaling pathways it downregulates FLT3/STAT5 phosphorylation and induces G1-phase arrest and apoptosis in FLT3-mutated leukemia cells while promoting G2/M arrest via reduced histone H3 phosphorylation in FLT3 wild-type cells KW 2449 is applied in research investigating kinase-driven leukemias and resistance mechanisms to targeted therapies
Medchemexpress LLC CAY 10465 | 688348-33-6 | 98.3% | 317.13 | 100 MG
CAY 10465 is a selective and high-affinity Aryl Hydrocarbon Receptor (AhR) agonist, with a Ki of 0.2 nM. It demonstrates no effect on the estrogen receptor (Ki >100000 nM). In vitro, CAY 10465 (at concentrations from 0.01 nM to 100 μM) has been shown to reduce apolipoprotein A-I (apo A-I) levels in HepG2 cells and inhibit the synthesis of this protein.
- Selective AhR agonist: High affinity for AhR with a Ki of 0.2 nM.
- No estrogen receptor effect: Shows no activity on the estrogen receptor (Ki >100000 nM).
- Inhibits apolipoprotein A-I: Reduces apo A-I levels and inhibits its synthesis in HepG2 cells.
- Appearance: Solid, white to off-white.
- Storage:
Powder: -20°C for 3 years, 4°C for 2 years.
In solvent: -80°C for 2 years, -20°C for 1 year.
Medchemexpress LLC CAY 10465 50mg | 688348-33-6 | 98.3% | 317.13 | 50 MG
CAY 10465 is a selective and high-affinity AhR agonist, with a Ki of 0.2 nM, and shows no effect on estrogen receptor (Ki >100000 nM).
- Is a selective and high-affinity AhR receptor agonist, with a Ki of 0.2 nM, and shows no effect on estrogen receptor (Ki >100000 nM).
- Reduces apolipoprotein A-I (apo A-I) levels in HepG2 cells, and inhibits the synthesis of the protein (0.01 nM-100 μM).
![Medchemexpress LLC [4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone | 1000669-72-6 | MFCD18385006 | 99.9% | 332.40 g·mol-1 | C20H20N4O | 100 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000244548.png-250.jpg)
Medchemexpress LLC [4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone | 1000669-72-6 | MFCD18385006 | 99.9% | 332.40 g·mol-1 | C20H20N4O | 100 MG
KW-2449 is a small-molecule, multi-targeted kinase inhibitor used in research to study signaling pathways and leukemia models. Supplied as a high-purity white powder, it is characterized by the molecular formula C20H20N4O and a molecular weight of 332.40 g·mol-1.
- Multi-targeted kinase inhibition: inhibits FLT3, ABL, ABL T315I, and Aurora kinases at low nanomolar IC50s.
- High purity: reported 99.91% purity suitable for biochemical and cell-based assays.
- Solid powder form: convenient for dissolution in common organic solvents and buffers.
- Well-characterized: SMILES and molecular properties available for computational and analytical use.
- For research use only: not intended for human or clinical use.